US Bancorp DE Sells 41,982 Shares of AbbVie Inc. $ABBV

US Bancorp DE reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 1.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,358,212 shares of the company’s stock after selling 41,982 shares during the quarter. US Bancorp DE’s holdings in AbbVie were worth $538,830,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ABBV. Centennial Wealth Advisory LLC boosted its position in shares of AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after acquiring an additional 45 shares during the last quarter. Weil Company Inc. grew its position in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after acquiring an additional 46 shares in the last quarter. Hardin Capital Partners LLC raised its position in AbbVie by 1.4% during the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after purchasing an additional 46 shares in the last quarter. Inlet Private Wealth LLC lifted its stake in AbbVie by 0.3% during the third quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock worth $3,937,000 after purchasing an additional 47 shares during the last quarter. Finally, D.B. Root & Company LLC increased its position in shares of AbbVie by 4.3% during the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company’s stock valued at $267,000 after purchasing an additional 47 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 3.3%

Shares of ABBV opened at $204.20 on Thursday. The stock has a market capitalization of $361.06 billion, a P/E ratio of 86.53, a PEG ratio of 0.71 and a beta of 0.38. AbbVie Inc. has a twelve month low of $176.57 and a twelve month high of $244.81. The firm has a fifty day simple moving average of $214.80 and a two-hundred day simple moving average of $221.67.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.01 by ($0.36). The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 EPS. Sell-side analysts expect that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.06% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 revenue beat and companyraised full?year adjusted EPS guidance, driven by strong Skyrizi and Rinvoq sales and strength in neuroscience (Botox/Vraylar). That top?line beat and guidance lift are the main reasons the stock is trading higher today. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: AbbVie filed for FDA approval to expand Rinvoq (upadacitinib) to severe alopecia areata and reported strong Phase 3 data—successful label expansion would broaden a high?growth franchise and support longer?term revenue upside. AbbVie Submits Application to FDA for Upadacitinib
• Neutral Sentiment: AbbVie took a strategic option/warrant position with Kestrel (KRAS program) and continues external R&D partnerships (e.g., EvolveImmune milestone) — these expand oncology exposure but are longer?dated potential drivers rather than immediate EPS levers. AbbVie sinks talons into KRAS with right to buy Kestrel
• Negative Sentiment: Adjusted EPS was reported at $2.65 — while many outlets framed results as a beat on revenue and guidance, EPS compared mixedly to different consensus numbers (some providers showed a slight miss/on?par), which has created some investor push?pull and intra?day volatility. AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates
• Negative Sentiment: Erste Group slightly trimmed its FY2026 and FY2027 EPS forecasts (FY26 to $14.13 from $14.55; FY27 to $16.10 from $16.16) — modest analyst downgrades add downward pressure, though cuts are small relative to the company’s raised 2026 guidance range. Erste Group analyst note (via MarketBeat)

Analysts Set New Price Targets

A number of research analysts have commented on ABBV shares. UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Guggenheim boosted their price target on shares of AbbVie from $242.00 to $249.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $252.38.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.